Want to see HK:2251 full AI Analyst Report?
2251 Stock Chart & Stats
HK$12.44
-HK$0.02(-0.17%)
At close: 4:00 PM EST
HK$12.44
-HK$0.02(-0.17%)
Day’s Range― - ―
52-Week RangeHK$6.95 - HK$14.40
Previous CloseN/A
Volume16.00K
Average Volume (3M)88.97K
Market Cap
HK$921.19M
Enterprise ValueHK$363.09
Total Cash (Recent Filing)HK$680.28M
Total Debt (Recent Filing)HK$26.04M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding101,955,610
10 Day Avg. Volume136,820
30 Day Avg. Volume88,972
Financial Highlights & Ratios
PEG Ratio0.47
Price to Book (P/B)0.85
Price to Sales (P/S)6.06
P/FCF Ratio-49.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.37
Revenue Forecast (FY)HK$251.57M
Bulls Say, Bears Say
Bulls Say
AI Medical Imaging PlatformA focused AI software model addresses image analysis, screening, triage, and workflow efficiency for healthcare providers. Integration with existing imaging equipment and hospital IT systems can support practical adoption and create durable relevance as providers digitize clinical processes.
Improving Revenue And Gross MarginThe recovery in revenue growth alongside a substantial gross-margin expansion indicates improving commercial momentum and unit economics. If maintained, stronger gross profitability can provide more resources for product development, customer acquisition, and progress toward sustainable operating profitability.
Conservative Balance SheetVery low leverage gives the company greater financial flexibility while limiting interest and refinancing pressure. This stronger capitalization can help preserve investment capacity for AI products and market development, even though profitability and returns on capital remain unresolved constraints.
Bears Say
Continued Net LossesDespite better revenue growth and gross margins, the company has not yet converted its business model into sustainable operating or net profit. Continued losses can consume capital, limit internally funded expansion, and make long-term earnings power dependent on further execution improvements.
Unreliable Cash GenerationNegative operating and free cash flow means reported commercial improvement is not yet translating into dependable cash conversion. The multi-year volatility increases execution risk and may constrain the company’s ability to fund product investment and expansion without relying on its balance-sheet resources.
Persistently Negative Shareholder ReturnsNegative ROE across the reported years shows that shareholder capital has not yet generated positive returns. This reinforces that the company’s strong capitalization is defensive rather than productive today, and that sustained profitability is required before financial strength becomes efficient value creation.
Beijing Airdoc Technology Co. Ltd. Class H News
2251 FAQ
What was Beijing Airdoc Technology Co. Ltd. Class H’s price range in the past 12 months?
Beijing Airdoc Technology Co. Ltd. Class H lowest stock price was HK$6.95 and its highest was HK$14.40 in the past 12 months.
What is Beijing Airdoc Technology Co. Ltd. Class H’s market cap?
Beijing Airdoc Technology Co. Ltd. Class H’s market cap is HK$921.19M.
When is Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date?
Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 182 days.
How were Beijing Airdoc Technology Co. Ltd. Class H’s earnings last quarter?
Beijing Airdoc Technology Co. Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -HK$0.561 earnings per share for the quarter.
Is Beijing Airdoc Technology Co. Ltd. Class H overvalued?
According to Wall Street analysts Beijing Airdoc Technology Co. Ltd. Class H’s price is currently Overvalued.
Does Beijing Airdoc Technology Co. Ltd. Class H pay dividends?
Beijing Airdoc Technology Co. Ltd. Class H does not currently pay dividends.
What is Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate?
Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Airdoc Technology Co. Ltd. Class H have?
Beijing Airdoc Technology Co. Ltd. Class H has 101,955,610 shares outstanding.
What happened to Beijing Airdoc Technology Co. Ltd. Class H’s price movement after its last earnings report?
Beijing Airdoc Technology Co. Ltd. Class H reported an EPS of -HK$0.561 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beijing Airdoc Technology Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2251
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Airdoc Technology Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Beijing Airdoc Technology Co. Ltd. Class H
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
Technical Analysis
Ping An Healthcare and Technology Company
―
Yidu Tech, Inc.
―
Chaoju Eye Care Holdings Ltd.
―
C-MER Eye Care Holdings Limited
―
Zhaoke Ophthalmology Ltd.
―